ABSTRACT
The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.
Subject(s)
Flavonoids/toxicity , Maackia , Phenols/toxicity , Abnormalities, Drug-Induced/etiology , Allergens/toxicity , Animals , Dogs , Female , Flavonoids/immunology , Isoflavones/immunology , Isoflavones/toxicity , Male , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Mutagenicity Tests , Phenols/immunology , Plant Extracts/immunology , Plant Extracts/toxicity , Polyphenols , Pregnancy , Rats , Reproduction/drug effects , Stilbenes/immunology , Stilbenes/toxicity , Toxicity Tests, Acute , Toxicity Tests, ChronicABSTRACT
Detailed preclinical study of the safety of the new antiviral agent iodantipyrine was conducted. In LD50 parameters it was found to be related to moderately toxic drugs. Long-term administration in doses of 50, 100, and 250 mg/kg did not cause any essential functional and structural disorders in the organs and systems of rats and dogs. Iodantipyrine does not possess mutagenic and allergenic properties and does not affect the reproductive function.